Adimmune Corporation (TPE:4142)

Market Cap	7.63B -1.6%
Revenue (ttm)	1.37B -15.1%
Net Income	-143.62M
EPS	-0.34
Shares Out	421.51M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,459,883
Open	18.15
Previous Close	18.10
Day's Range	18.05 - 18.30
52-Week Range	16.40 - 22.50
Beta	0.27
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 12, 2026

About Adimmune

Adimmune Corporation engages in the development, manufacture, and distribution of vaccines and other biological products in Taiwan, the United States, China, and internationally. The company offers AdimFlu-S, a quadrivalent influenza vaccine; suspensions for injection influenza vaccines; and tetanus toxoid alum precipitated product for the prevention of tetanus after injury. It also develops AdimrSC-2f, a subunit protein-based vaccine for the prevention of COVID-19; H5N1 vaccine; and cell culture-derived Japanese encephalitis vaccine. The compa...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1965
• Employees: 564
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 4142

Financial Performance

In 2025, Adimmune's revenue was 1.40 billion, a decrease of -9.99% compared to the previous year's 1.56 billion. Losses were -239.89 million, -1.18% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 30, 2026

Data Sources Report a data error